Merrimack Pharmaceuticals Completes Enrollment of One Cohort in Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer

[at noodls] – CAMBRIDGE, Mass., April 15, 2013 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in one group of a two-cohort randomized Phase … more

View todays social media effects on MACK

View the latest stocks trending across Twitter. Click to view dashboard

See who Merrimack is hiring next, click here to view